8.94
전일 마감가:
$9.09
열려 있는:
$9.17
하루 거래량:
67,466
Relative Volume:
0.58
시가총액:
$128.90M
수익:
$166.88M
순이익/손실:
$-74.18M
주가수익비율:
-1.7633
EPS:
-5.07
순현금흐름:
$1.14M
1주 성능:
-4.69%
1개월 성능:
+7.07%
6개월 성능:
-47.50%
1년 성능:
-64.68%
Anika Therapeutics Inc Stock (ANIK) Company Profile
명칭
Anika Therapeutics Inc
전화
(781) 457-9000
주소
32 WIGGINS AVENUE, BEDFORD, MA
ANIK을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ANIK
Anika Therapeutics Inc
|
8.94 | 131.06M | 166.88M | -74.18M | 1.14M | -5.07 |
![]()
ZTS
Zoetis Inc
|
153.32 | 67.90B | 9.39B | 2.62B | 2.22B | 5.81 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.40 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
![]()
HLN
Haleon Plc Adr
|
9.80 | 44.04B | 14.26B | 1.98B | 2.47B | 0.4347 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.95 | 21.20B | 16.70B | -157.13M | 1.19B | -0.155 |
![]()
UTHR
United Therapeutics Corp
|
400.52 | 17.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-17 | 개시 | B. Riley Securities | Buy |
2024-11-01 | 재확인 | Barrington Research | Outperform |
2023-08-14 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
2023-03-07 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
2022-11-09 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
2022-10-14 | 재개 | Stephens | Equal-Weight |
2022-03-09 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
2022-03-09 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
2021-11-16 | 개시 | Stephens | Overweight |
2021-07-16 | 개시 | UBS | Neutral |
2020-12-16 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
2020-05-08 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
2020-01-21 | 업그레이드 | Sidoti | Neutral → Buy |
2020-01-10 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
2019-11-05 | 개시 | BWS Financial | Sell |
2019-09-24 | 재확인 | Barrington Research | Outperform |
2019-09-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
2019-07-25 | 업그레이드 | First Analysis Sec | Neutral → Strong Buy |
2019-02-22 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
2019-02-22 | 다운그레이드 | Sidoti | Buy → Neutral |
2018-07-27 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
2018-06-20 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
2018-06-20 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
2018-05-04 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
2018-02-23 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
2018-01-24 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
2017-10-27 | 재확인 | Barrington Research | Outperform |
2016-05-09 | 업그레이드 | Singular Research | BUY - Long-Term → Buy |
2016-04-27 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
2016-02-26 | 재확인 | Barrington Research | Outperform |
모두보기
Anika Therapeutics Inc 주식(ANIK)의 최신 뉴스
Will Anika Therapeutics Inc. rebound enough to break even2025 Bull vs Bear & Smart Money Movement Alerts - Newser
Statistical indicators supporting Anika Therapeutics Inc.’s strengthInsider Buying & Expert-Curated Trade Recommendations - Newser
What data driven models say about Anika Therapeutics Inc.’s futureQuarterly Profit Summary & Long Hold Capital Preservation Tips - Newser
How cyclical is Anika Therapeutics Inc.’s revenue stream2025 Technical Overview & Consistent Profit Alerts - خودرو بانک
Does Anika Therapeutics Inc. have declining or rising EPSStop Loss & Weekly High Conviction Trade Ideas - خودرو بانک
Risk adjusted return profile for Anika Therapeutics Inc. analyzedJuly 2025 Update & Free Real-Time Market Sentiment Alerts - Newser
Can Anika Therapeutics Inc. expand into new marketsPortfolio Performance Report & Fast Gain Stock Trading Tips - خودرو بانک
Should you buy the dip on Anika Therapeutics Inc.July 2025 Intraday Action & Accurate Entry and Exit Point Alerts - خودرو بانک
Visual analytics tools that track Anika Therapeutics Inc. performanceJobs Report & Smart Swing Trading Alerts - Newser
Real time breakdown of Anika Therapeutics Inc. stock performanceMarket Performance Recap & Reliable Price Breakout Alerts - Newser
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Anika Therapeutics Announces Inducement Grants for New Hire Under Nasdaq Listing Rule 5635(c)(4) - AInvest
2,500 Shares at $9.15: Anika Therapeutics Awards Inducement Stock Options to New Non-Executive Hire - Stock Titan
Understanding Anika Therapeutics Inc.’s price movementJuly 2025 Highlights & Entry Point Confirmation Signals - Newser
Regression analysis insights on Anika Therapeutics Inc. performanceMarket Performance Report & Daily Entry Point Alerts - Newser
Price momentum metrics for Anika Therapeutics Inc. explainedPortfolio Gains Summary & Advanced Technical Analysis Signals - Newser
Does Anika Therapeutics Inc. fit your quant trading modelJuly 2025 Intraday Action & Community Consensus Stock Picks - Newser
Pomerantz LLP Investigates Potential Claims Involving Anika Therapeutics Investors - geneonline.com
Published on: 2025-09-04 09:02:32 - Newser
Will Anika Therapeutics Inc. stock recover after recent dropMarket Rally & Free Risk Controlled Daily Trade Plans - Newser
Is Anika Therapeutics Inc. stock bottoming outJuly 2025 Market Mood & Advanced Technical Analysis Signals - Newser
How hedge fund analytics apply to Anika Therapeutics Inc. stockFed Meeting & Risk Managed Investment Strategies - Newser
What to expect from Anika Therapeutics Inc. in the next 30 daysWeekly Profit Report & Verified Swing Trading Watchlist - Newser
Sentiment analysis tools applied to Anika Therapeutics Inc.Weekly Trade Review & Daily Chart Pattern Signal Reports - Newser
Live market analysis of Anika Therapeutics Inc.Market Performance Recap & Verified Technical Trade Signals - Newser
Is Anika Therapeutics Inc. gaining market shareBreakout Watch & Fast Entry and Exit Trade Plans - خودرو بانک
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc.ANIK - PR Newswire
How institutional ownership impacts Anika Therapeutics Inc. stock2025 Stock Rankings & Community Trade Idea Sharing Platform - Newser
Will Anika Therapeutics Inc. price bounce be sustainableWeekly Trade Report & Free Safe Capital Growth Stock Tips - Newser
Is Anika Therapeutics Inc. stock entering bullish territoryMarket Movers & Advanced Swing Trade Entry Plans - Newser
Will Anika Therapeutics Inc. benefit from geopolitical trendsInsider Selling & Daily Profit Focused Screening - خودرو بانک
Real time scanner hits for Anika Therapeutics Inc. explainedQuarterly Market Review & Smart Allocation Stock Tips - Newser
Tools to monitor Anika Therapeutics Inc. recovery probabilityJuly 2025 Recap & Expert Curated Trade Ideas - Newser
Is Anika Therapeutics Inc. forming a bottoming base2025 Winners & Losers & Long-Term Growth Plans - Newser
What are Anika Therapeutics Inc.’s recent SEC filings showingRate Cut & Entry and Exit Point Strategies - خودرو بانک
Tick level data insight on Anika Therapeutics Inc. volatility2025 Stock Rankings & Real-Time Volume Triggers - Newser
Using fundamentals and technicals on Anika Therapeutics Inc.2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - Newser
Can a trend reversal in Anika Therapeutics Inc. lead to recoveryWeekly Risk Report & Trade Opportunity Analysis Reports - Newser
Applying Wyckoff theory to Anika Therapeutics Inc. stockPortfolio Profit Report & Free Community Consensus Stock Picks - Newser
Aug Ideas: What are Anika Therapeutics Inc.’s technical support levels - خودرو بانک
Can you recover from losses in Anika Therapeutics Inc.Market Rally & Weekly Top Stock Performers List - Newser
Anika Therapeutics Inc (ANIK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anika Therapeutics Inc 주식 (ANIK) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
Nunes Anne | SVP, Chief Operations Officer |
Oct 01 '24 |
Option Exercise |
0.00 |
2,491 |
0 |
14,211 |
자본화:
|
볼륨(24시간):